// Auto-generated - do not edit
export const substanceName = "Dextroamphetamine";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Dextroamphetamine.md","displayName":"DrugBank","size":21639},{"id":"protestkit","fileName":"PROTESTKIT - Dextroamphetamine.json","displayName":"Protest Kit","size":4970},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - Dextroamphetamine.md","displayName":"PsychonautWiki","size":17474},{"id":"saferparty","fileName":"SAFERPARTY - Dextroamphetamine.md","displayName":"Safer Party","size":1532},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Dextroamphetamine.md","displayName":"TripSit Factsheets","size":387},{"id":"wikipedia","fileName":"WIKIPEDIA - Dextroamphetamine.md","displayName":"Wikipedia","size":43343}];
export const contents: Record<string, string> = {
  "drugbank": `# Dextroamphetamine
*Source: https://go.drugbank.com/drugs/DB01576*

## Overview

### Description

This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.

### Background

Dextroamphetamine is the dextrorotatory enantiomer of amphetamine
5
. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.
6
,
8

### Indication

Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD)
7
,
8
and narcolepsy.
8

### Pharmacodynamics

Dextroamphetamine is a noncatecholamine, sympathomimetic amine that acts as a CNS stimulant.
7
Dextroamphetamine raises systolic and diastolic blood pressure, acts as a weak bronchodilator, and also acts as a respiratory stimulant.
7
The general mechanism of action of dextroamphetamine has not been well established.
7

### Mechanism of Action

Synaptic vesicular amine transporter
Inducer
Sodium-dependent noradrenaline transporter
Negative modulator
Sodium-dependent dopamine transporter
Negative modulator

### Absorption

Bioavailability data of dextroamphetamine is not readily available, however there is no difference in bioavailability when taken with or without a meal.
8

### Metabolism

Dextroamphetamine is metabolized by cytochrome P-450 2D6 in the liver to 4-hydroxyamphetamine and later conjugated by sulfotransferase or glucoronyltransferase.
1
Hover over products below to view reaction partners
Dextroamphetamine
4-hydroxyamphetamine

### Half-life

11.75 hours.
8
In a study of post-stroke patients the half life was 16.0 hours in females and 12.4 hours in males.
5
Studies in healthy populations show a half life of 7.9 hours.
3

### Toxicity

Dextroamphetamine has been shown to be teratogenic and embryotoxic in mice at 41 times the maximum human dose.
8
These effects were not seen in rat or rabbit studies, and the effects on human pregnancy have not been studied.
8
The risk and benefit of use during pregnancy should be weighed as bone deformities, tracheoesophageal fistula, anal atresia, low birthweight, and withdrawl have been reported in the children of mothers who were taking dextroamphetamine during pregnancy.
8
Mothers should not take amphetamines while nursing as the drug is excreted in breast milk.
8
Long term effects of dextroamphetamine have not bee determined in pediatric patients and dextroamphetamine should be avoided in children under 3 years.
8

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Abatacept
The metabolism of Dextroamphetamine can be increased when combined with Abatacept.
Abiraterone
The metabolism of Dextroamphetamine can be decreased when combined with Abiraterone.
Acebutolol
The therapeutic efficacy of Acebutolol can be decreased when used in combination with Dextroamphetamine.
Aceclofenac
The risk or severity of hypertension can be increased when Dextroamphetamine is combined with Aceclofenac.
Acemetacin
The risk or severity of hypertension can be increased when Dextroamphetamine is combined with Acemetacin.

### Food Interactions

Avoid fruit juice. Fruit juice may acidify the gastrointestinal tract, decreasing absorption of amphetamines.

## Chemical Information

**DrugBank ID:** DB01576

**Synonyms:** (+)-(S)-amphetamine
(+)-amphetamine
(+)-α-methylphenethylamine
(+)-α-methylphenylethylamine
(S)-(+)-amphetamine
(S)-(+)-β-phenylisopropylamine
(S)-1-phenyl-2-aminopropane
(S)-1-phenyl-2-propylamine
(S)-amphetamine
(S)-α-methylbenzeneethanamine
(αS)-α-methylbenzeneethanamine
d-amphetamine
Desamfetamina
Dexamfetamina
Dexamfetamine
Dexamfetaminum
Dexamphetamine
Dexanfetamina
Dextroamphetamine

**Chemical Formula:** C
9
H
13
N

**SMILES:** C[C@H](N)CC1=CC=CC=C1

**Weight:** Average: 135.2062
Monoisotopic: 135.104799421

**IUPAC Name:** (2S)-1-phenylpropan-2-amine

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
US6384020
Yes
2002-05-07
2021-01-06
US
USRE42096
Yes
2011-02-01
2019-04-21
US
US6605300
Yes
2003-08-12
2019-04-21
US
US6322819
Yes
2001-11-27
2019-04-21
US
USRE41148
Yes
2010-02-23
2019-04-21
US
US8632802
No
2014-01-21
2025-10-07
US
US9034370
No
2015-05-19
2025-10-07
US
US9173857
No
2015-11-03
2026-05-12
US
US6913768
No
2005-07-05
2023-05-24
US
US8846100
No
2014-09-30
2029-08-24
US
US9456993
No
2016-10-04
2033-10-24
US
US9474722
No
2016-10-25
2033-10-24
US
US8591941
No
2013-11-26
2025-10-07
US
US11559501
No
2023-01-24
2042-01-06
US

### Indicated Conditions

2

### Phase 0

4

### Phase 1

10

### Phase 2

24

### Phase 3

3

### Phase 4

19

### Therapeutic Categories

Amphetamines
Central Nervous System
Stimulants

### Summary

Dextroamphetamine
is a sympathomimetic agent used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.

### Brand Names

Adderall, Dexedrine, Mydayis, Procentra, Xelstrym, Zenzedi

### Generic Name

Dextroamphetamine

### DrugBank Accession Number

DB01576

### Groups

Approved, Illicit, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Dextroamphetamine (DB01576)
×
Close

### External IDs

NSC-73713

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Used in combination to manage
Attention deficit hyperactivity disorder
Combination Product in combination with:
Amphetamine (DB00182)
••••••••••••
Create Account
•••••
Used in combination to manage
Attention deficit hyperactivity disorder
Combination Product in combination with:
Amphetamine (DB00182)
••••••••••••
Create Account
••••••••••
Used in combination to manage
Attention deficit hyperactivity disorder
Combination Product in combination with:
Amphetamine (DB00182)
••••••••••••
Create Account
••••••••
Management of
Attention deficit hyperactivity disorder
••••••••••••
Create Account
Management of
Narcolepsy
••••••••••••
Create Account
Create Account

### Mechanism of action

The exact mechanism of amphetamines as a class is not known. Dextroamphetamine acts by preventing reuptake, increasing release, and stimulating reverse-transport of dopamine in synaptic clefts in the striatum.
4
Newer evidence shows amphetamines may also alter the number of dopamine transporters in synaptic clefts.
2
Target
Actions
Organism
A
Synaptic vesicular amine transporter
inducer
Humans
A
Sodium-dependent noradrenaline transporter
negative modulator
Humans
A
Sodium-dependent dopamine transporter
negative modulator
Humans
U
Trace amine-associated receptor 1
agonist
Humans
U
Alpha-1B adrenergic receptor
antagonist
Humans
U
Alpha adrenergic receptor
inhibitor
inducer
Humans

### Volume of distribution

195L.
3

### Route of elimination

A third of the drug is eliminated renally.
5

### Clearance

17L/h.
3

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Dextroamphetamine adipate
YYI1A8W4TQ
64770-52-1
OFCJKOOVFDGTLY-QRPNPIFTSA-N
Dextroamphetamine saccharate
G83415V073
350708-40-6
CXFNVDBOUVJOQO-OUDZKKFGSA-N
Dextroamphetamine sulfate
JJ768O327N
51-63-8
SOFQDLYSFOWTJX-QRPNPIFTSA-N

### Product Images

Previous
Next

### International/Other Brands

Attentin (Medice)
/
Dexamphetamine (Sigma)

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Adderall XR
Capsule, extended release
6.25 mg
Oral
Takeda Italia S.P.A.
2004-01-30
Not applicable
Canada
Adderall XR
Capsule, extended release
6.25 mg
Oral
Takeda Italia S.P.A.
2004-01-30
Not applicable
Canada
Dexedrine
Tablet
5 mg
Oral
Endo Operations Ltd.
1992-12-31
Not applicable
Canada
Dexedrine
Capsule, extended release
5 mg/1
Oral
Glaxosmithkline Inc
2007-11-14
2012-05-31
US
Dexedrine
Tablet
5 mg/1
Oral
Glaxosmithkline Inc
2007-04-10
Not applicable
US

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Apo-dextroamphetamine SR
Capsule, extended release
15 mg
Oral
Apotex Corporation
Not applicable
Not applicable
Canada
Apo-dextroamphetamine SR
Capsule, extended release
10 mg
Oral
Apotex Corporation
Not applicable
Not applicable
Canada
Dexedrine
Tablet
10 mg/1
Oral
Amedra Pharmaceuticals LLC
2014-07-01
2016-09-30
US
Dexedrine
Tablet
5 mg/1
Oral
Physicians Total Care, Inc.
2004-12-16
2011-05-31
US
Dexedrine
Tablet
5 mg/1
Oral
Amedra Pharmaceuticals LLC
2014-07-01
2016-09-30
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Adderall
Dextroamphetamine saccharate
(5 mg/1)
+
Dextroamphetamine sulfate
(5 mg/1)
+
Amphetamine aspartate
(5 mg/1)
+
Amphetamine sulfate
(5 mg/1)
Tablet
Oral
bryant ranch prepack
1996-02-13
Not applicable
US
Adderall
Dextroamphetamine saccharate
(5 mg/1)
+
Dextroamphetamine sulfate
(5 mg/1)
+
Amphetamine aspartate
(5 mg/1)
+
Amphetamine sulfate
(5 mg/1)
Tablet
Oral
bryant ranch prepack
1996-02-13
Not applicable
US
Adderall
Dextroamphetamine saccharate
(2.5 mg/1)
+
Dextroamphetamine sulfate
(2.5 mg/1)
+
Amphetamine aspartate
(2.5 mg/1)
+
Amphetamine sulfate
(2.5 mg/1)
Tablet
Oral
bryant ranch prepack
1996-02-13
Not applicable
US
Adderall
Dextroamphetamine saccharate
(2.5 mg/1)
+
Dextroamphetamine sulfate
(2.5 mg/1)
+
Amphetamine aspartate
(2.5 mg/1)
+
Amphetamine sulfate
(2.5 mg/1)
Tablet
Oral
bryant ranch prepack
1996-02-13
Not applicable
US
Adderall
Dextroamphetamine saccharate
(1.25 mg/1)
+
Dextroamphetamine sulfate
(1.25 mg/1)
+
Amphetamine aspartate
(1.25 mg/1)
+
Amphetamine sulfate
(1.25 mg/1)
Tablet
Oral
Physicians Total Care, Inc.
1997-10-02
2011-07-31
US

### ATC Codes

N06BA02 — Dexamfetamine
N06BA — Centrally acting sympathomimetics
N06B — PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Agents producing tachycardia
Agents that produce hypertension
Amines
Amphetamines
Central Nervous System Agents
Central Nervous System Stimulants
Central Nervous System Stimulation
Centrally Acting Sympathomimetics
Cytochrome P-450 CYP2D6 Substrates
Cytochrome P-450 Substrates
Dopamine Agents
Dopamine Uptake Inhibitors
Ethylamines
Membrane Transport Modulators
Nervous System
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Phenethylamines
Psychoanaleptics
Psychostimulants, Agents Used for ADHD and Nootropics
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Sympathomimetics

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes
/
Aralkylamines
/
Organopnictogen compounds
/
Monoalkylamines
/
Hydrocarbon derivatives
Substituents
Amine
/
Amphetamine or derivatives
/
Aralkylamine
/
Aromatic homomonocyclic compound
/
Hydrocarbon derivative
/
Organic nitrogen compound
/
Organonitrogen compound
/
Organopnictogen compound
/
Phenylpropane
/
Primary aliphatic amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
amphetamine (
CHEBI:4469
)

### Kingdom

Organic compounds

### Super Class

Benzenoids

### Class

Benzene and substituted derivatives

### Sub Class

Phenethylamines

### Direct Parent

Amphetamines and derivatives

### Alternative Parents

Phenylpropanes
/
Aralkylamines
/
Organopnictogen compounds
/
Monoalkylamines
/
Hydrocarbon derivatives

### Substituents

Amine
/
Amphetamine or derivatives
/
Aralkylamine
/
Aromatic homomonocyclic compound
/
Hydrocarbon derivative
/
Organic nitrogen compound
/
Organonitrogen compound
/
Organopnictogen compound
/
Phenylpropane
/
Primary aliphatic amine

### Molecular Framework

Aromatic homomonocyclic compounds

### External Descriptors

amphetamine (
CHEBI:4469
)

### Affected organisms

Humans and other mammals

### UNII

TZ47U051FI

### CAS number

51-64-9

### InChI Key

KWTSXDURSIMDCE-QMMMGPOBSA-N

### InChI

InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1

### Synthesis Reference

Nabenhauer, F.P.; US. Patent 2,276,508; March 17,1942; assigned to Smith, Kline & French
Laboratories.

### General References

de la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, Pichini S: Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet. 2004;43(3):157-85. doi: 10.2165/00003088-200443030-00002. [
Article
]
Saunders C, Galli A: Insights in how amphetamine ROCKs (Rho-associated containing kinase) membrane protein trafficking. Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):15538-9. doi: 10.1073/pnas.1520960112. Epub 2015 Nov 25. [
Article
]
Dolder PC, Strajhar P, Vizeli P, Hammann F, Odermatt A, Liechti ME: Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. Front Pharmacol. 2017 Sep 7;8:617. doi: 10.3389/fphar.2017.00617. eCollection 2017. [
Article
]
Calipari ES, Ferris MJ: Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci. 2013 May 22;33(21):8923-5. doi: 10.1523/JNEUROSCI.1033-13.2013. [
Article
]
Martinsson L, Yang X, Beck O, Wahlgren NG, Eksborg S: Pharmacokinetics of dexamphetamine in acute stroke. Clin Neuropharmacol. 2003 Sep-Oct;26(5):270-6. [
Article
]
FDA Drug Approval Package for Dextroamphetamine [
Link
]
FDA Approved Drug Products: Adderall (dextroamphetamine) capsule [
Link
]
FDA Approved Drug Products: DEXEDRINE (dextroamphetamine sulfate) SPANSULE® sustained-release capsules, CII [
Link
]

### External Links

Human Metabolome Database
HMDB0015516
KEGG Drug
D03740
KEGG Compound
C07884
PubChem Compound
5826
PubChem Substance
46506252
ChemSpider
5621
BindingDB
50022723
RxNav
3288
ChEBI
4469
ChEMBL
CHEMBL612
ZINC
ZINC000006021033
Therapeutic Targets Database
DAP001470
PharmGKB
PA448408
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
1WE
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dextroamphetamine

### Human Metabolome Database

HMDB0015516

### KEGG Drug

D03740

### KEGG Compound

C07884

### PubChem Compound

5826

### PubChem Substance

46506252

### ChemSpider

5621

### BindingDB

50022723

### RxNav

3288

### ChEBI

4469

### ChEMBL

CHEMBL612

### ZINC

ZINC000006021033

### Therapeutic Targets Database

DAP001470

### PharmGKB

PA448408

### Guide to Pharmacology

GtP Drug Page

### PDBe Ligand

1WE

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Dextroamphetamine

### PDB Entries

4lar
/
4xp9
/
8jso
/
8tgh
/
8uco

### MSDS

Download
(145 KB)

### Packagers

Abbott Laboratories Ltd.
Actavis Group
Auriga Pharmaceuticals LLC
Barr Pharmaceuticals
Bryant Ranch Prepack
Cardinal Health
Catalent Pharma Solutions
Corepharma LLC
D.M. Graham Laboratories Inc.
Dispensing Solutions
DSM Corp.
Eon Labs
Ethex Corp.
GlaxoSmithKline Inc.
Global Pharmaceuticals
Lundbeck Inc.
Mallinckrodt Inc.
Mikart Inc.
Nucare Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Physicians Total Care Inc.
Professional Co.
Ranbaxy Laboratories
Shire Inc.
Stat Rx Usa
Tiber Pharmaceuticals LLC

### Dosage Forms

Form
Route
Strength
Capsule, extended release
Oral
6.25 mg
Capsule, extended release
Oral
10 mg/1
Capsule, extended release
Oral
15 mg/1
Capsule, extended release
Oral
5 mg/1
Tablet
Oral
5 mg
Tablet
Oral
5 mg/1
Capsule, extended release
Oral
10 mg
Capsule, extended release
Oral
15 mg
Capsule
Oral
Capsule, extended release
Oral
Tablet
Oral
Solution
Oral
5 mg/5mL
Tablet
Oral
10 mg/1
Liquid
Oral
5 mg/5mL
Patch, extended release
Topical
13.5 mg/1
Patch, extended release
Topical
18 mg/1
Patch, extended release
Topical
4.5 mg/1
Patch, extended release
Topical
9 mg/1
Tablet
Oral
15 mg/1
Tablet
Oral
2.5 mg/1
Tablet
Oral
20 mg/1
Tablet
Oral
30 mg/1
Tablet
Oral
7.5 mg/1

### Prices

Unit description
Cost
Unit
D-amphetamine sulfate powder
900.0USD
g
Desoxyn 5 mg tablet
5.1USD
tablet
Dexedrine 15 mg 24 Hour Capsule
4.22USD
capsule
Dextroamphetamine Sulfate CR 15 mg 24 Hour Capsule
3.47USD
capsule
Dexedrine 10 mg 24 Hour Capsule
3.23USD
capsule
Dexedrine 5 mg 24 Hour Capsule
3.0USD
capsule
Dextroamphetamine Sulfate CR 10 mg 24 Hour Capsule
2.96USD
capsule
Dexedrine spansule 15 mg
2.45USD
each
Dextroamphetamine Sulfate CR 5 mg 24 Hour Capsule
2.06USD
capsule
Dexedrine spansule 10 mg
1.91USD
each
Dexedrine spansule 5 mg
1.91USD
each
Dexedrine 15 mg Sustained-Release Capsule
1.08USD
capsule
Dextroamphetamine Sulfate 10 mg tablet
0.92USD
tablet
Dexedrine 10 mg Sustained-Release Capsule
0.89USD
capsule
Dextroamphetamine Sulfate 5 mg tablet
0.65USD
tablet
Dexedrine 5 mg Tablet
0.62USD
tablet
Dextroamphetamine 10 mg tablet
0.56USD
tablet
Dextrostat 10 mg tablet
0.48USD
tablet
Dextroamphetamine 5 mg tablet
0.28USD
tablet
Dextrostat 5 mg tablet
0.25USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Liquid

### Experimental Properties

Property
Value
Source
melting point (°C)
-98
[MSDS]
boiling point (°C)
64.7
[MSDS]
water solubility
Moderately Soluble
[MSDS]

### Predicted Properties

Property
Value
Source
Water Solubility
1.74 mg/mL
ALOGPS
logP
1.85
ALOGPS
logP
1.8
Chemaxon
logS
-1.9
ALOGPS
pKa (Strongest Basic)
10.01
Chemaxon
Physiological Charge
1
Chemaxon
Hydrogen Acceptor Count
1
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
26.02 Å
2
Chemaxon
Rotatable Bond Count
2
Chemaxon
Refractivity
43.71 m
3
·mol
-1
Chemaxon
Polarizability
16.08 Å
3
Chemaxon
Number of Rings
1
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
No
Chemaxon
Veber's Rule
Yes
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9972
Blood Brain Barrier
+
0.9565
Caco-2 permeable
+
0.8395
P-glycoprotein substrate
Non-substrate
0.7379
P-glycoprotein inhibitor I
Non-inhibitor
0.9519
P-glycoprotein inhibitor II
Non-inhibitor
0.9859
Renal organic cation transporter
Non-inhibitor
0.8002
CYP450 2C9 substrate
Non-substrate
0.8114
CYP450 2D6 substrate
Substrate
0.8919
CYP450 3A4 substrate
Non-substrate
0.795
CYP450 1A2 substrate
Non-inhibitor
0.5697
CYP450 2C9 inhibitor
Non-inhibitor
0.9313
CYP450 2D6 inhibitor
Inhibitor
0.657
CYP450 2C19 inhibitor
Non-inhibitor
0.8445
CYP450 3A4 inhibitor
Non-inhibitor
0.8709
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.8732
Ames test
Non AMES toxic
0.93
Carcinogenicity
Non-carcinogens
0.6869
Biodegradation
Not ready biodegradable
0.6575
Rat acute toxicity
3.2491 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9452
hERG inhibition (predictor II)
Non-inhibitor
0.9231
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(6.85 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0006-9100000000-41224b447ebed58b4d86
Mass Spectrum (Electron Ionization)
MS
splash10-0006-9000000000-f40d32a5bced4783345a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00kf-9500000000-5b99f81fa83e55e904bc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-015c-2900000000-6b67a9199ff61ba7506b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0006-9400000000-6052d3a0dac0780497c5
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9300000000-44c12c2637a4565bf91a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0006-9000000000-037fb8f36c878115fcc5
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9000000000-c70e8a43d2a9c0d44a49
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
130.813261
predicted
DarkChem Lite v0.1.0
[M-H]-
129.93782
predicted
DeepCCS 1.0 (2019)
[M+H]+
131.854361
predicted
DarkChem Lite v0.1.0
[M+H]+
133.15218
predicted
DeepCCS 1.0 (2019)
[M+Na]+
131.248361
predicted
DarkChem Lite v0.1.0
[M+Na]+
142.44734
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### General Function

Mediates sodium- and chloride-dependent transport of dopamine (PubMed:10375632, PubMed:11093780, PubMed:1406597, PubMed:15505207, PubMed:19478460, PubMed:39112701, PubMed:39112703, PubMed:39112705, PubMed:8302271). Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling (By similarity)

### Specific Function

amine binding

### Gene Name

SLC6A3

### Uniprot ID

Q01959

### Uniprot Name

Sodium-dependent dopamine transporter

### Molecular Weight

68494.255 Da

### Curator comments

There are limited data in the literature to support this target action. Adrenergic receptors are possible targets for dextroamphetamine based on indirect evidence.

`,
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/Dextroamphetamine",
  "experiencesUrl": "https://www.reddit.com/search/?q=Dextroamphetamine",
  "name": "Dextroamphetamine",
  "aliases": [
    "attentin",
    "d-amphetamine,dexedrine",
    "dex",
    "dexamphetamine"
  ],
  "aliasesStr": "attentin,d-amphetamine,dexedrine,dex,dexamphetamine",
  "summary": null,
  "reagents": null,
  "classes": {
    "chemical": [
      "Substituted phenethylamines",
      "Amphetamine"
    ],
    "psychoactive": [
      "Stimulants"
    ]
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "3.75 mg"
        },
        {
          "name": "Light",
          "value": "3.75 - 10 mg"
        },
        {
          "name": "Common",
          "value": "10 - 16 mg"
        },
        {
          "name": "Strong",
          "value": "16 - 30 mg"
        },
        {
          "name": "Heavy",
          "value": "30 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.25 - 0.5 hours"
        },
        {
          "name": "Come up",
          "value": "0.5 - 1.0 hours"
        },
        {
          "name": "Peak",
          "value": "2.5 - 4.0 hours"
        },
        {
          "name": "Offset",
          "value": "2.0 - 3.0 hours"
        },
        {
          "name": "Total",
          "value": "6.0 - 8.0 hours"
        },
        {
          "name": "After effects",
          "value": "3.0 - 6.0 hours"
        }
      ],
      "bioavailability": "20-25-75%+"
    },
    {
      "name": "Insufflated",
      "dosage": [
        {
          "name": "Threshold",
          "value": "3 mg"
        },
        {
          "name": "Light",
          "value": "3 - 7.5 mg"
        },
        {
          "name": "Common",
          "value": "7.5 - 12 mg"
        },
        {
          "name": "Strong",
          "value": "12 - 21.5 mg"
        },
        {
          "name": "Heavy",
          "value": "21.5 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.02 - 0.08 hours"
        },
        {
          "name": "Come up",
          "value": "0.08 - 0.25 hours"
        },
        {
          "name": "Peak",
          "value": "1.0 - 2.0 hours"
        },
        {
          "name": "Offset",
          "value": "1.5 - 3.0 hours"
        },
        {
          "name": "Total",
          "value": "3.0 - 6.0 hours"
        },
        {
          "name": "After effects",
          "value": "2.0 - 4.0 hours"
        }
      ]
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Unsafe"
    },
    {
      "name": "2C-x",
      "status": "Caution"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Unsafe"
    },
    {
      "name": "Alcohol",
      "status": "Caution"
    },
    {
      "name": "Benzos",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Caffeine",
      "status": "Caution"
    },
    {
      "name": "Cannabis",
      "status": "Caution"
    },
    {
      "name": "Cocaine",
      "status": "Caution"
    },
    {
      "name": "DMT",
      "status": "Caution"
    },
    {
      "name": "DOx",
      "status": "Unsafe"
    },
    {
      "name": "DXM",
      "status": "Unsafe"
    },
    {
      "name": "GHB/GBL",
      "status": "Caution"
    },
    {
      "name": "Gabapentinoids",
      "status": "Caution"
    },
    {
      "name": "Ketamine",
      "status": "Caution"
    },
    {
      "name": "LSD",
      "status": "Caution"
    },
    {
      "name": "MAOIs",
      "status": "Dangerous"
    },
    {
      "name": "MDMA",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MMC class",
      "status": "Unsafe"
    },
    {
      "name": "MXE",
      "status": "Caution"
    },
    {
      "name": "Mescaline",
      "status": "Caution"
    },
    {
      "name": "Mushrooms",
      "status": "Caution"
    },
    {
      "name": "NBOMes",
      "status": "Unsafe"
    },
    {
      "name": "Nitrous",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Opioids",
      "status": "Caution"
    },
    {
      "name": "PDA5",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "PVP class",
      "status": "Unsafe"
    },
    {
      "name": "Poppers",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "SSRIs",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": "",
  "categorized_effects": {
    "Physical effects": [
      "vasoconstriction",
      "temporary erectile dysfunction",
      "increased heart rate",
      "increased blood pressure",
      "teeth grinding"
    ],
    "Mental effects": [],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "psychonautwiki": `# Dextroamphetamine
*Source: https://psychonautwiki.org/wiki/Dextroamphetamine*

## Dosage & Duration

### Oral

**Dosage:**
- Bioavailability: 20-25[1]-75%+[2]
- Threshold: 3.75 mg
- Light: 3.75 - 10 mg
- Common: 10 - 16 mg
- Strong: 16 - 30 mg
- Heavy: 30 mg +

**Duration:**
- Total: 6 - 8 hours
- Onset: 15 - 30 minutes
- Come up: 30 - 60 minutes
- Peak: 2.5 - 4 hours
- Offset: 2 - 3 hours
- After effects: 3 - 6 hours

### Insufflated

**Dosage:**
- Threshold: 3 mg
- Light: 3 - 7.5 mg
- Common: 7.5 - 12 mg
- Strong: 12 - 21.5 mg
- Heavy: 21.5 mg +

**Duration:**
- Total: 3 - 6 hours
- Onset: 1 - 5 minutes
- Come up: 5 - 15 minutes
- Peak: 1 - 2 hours
- Offset: 1.5 - 3 hours
- After effects: 2 - 4 hours

**Dextroamphetamine** (also known as *Dexamphetamine, Dex, Dexies* , and sold under brand names like *[Adderall](https://en.wikipedia.org/wiki/Adderall)* , *[Dexedrine](https://www.webmd.com/drugs/2/drug-1636-9080/dextroamphetamine-sulfate-oral/dextroamphetamine-oral/details)* , and *[Zenzedi](https://zenzedi.com/)* ) is a central nervous system stimulant and the right-handed enantiomer of amphetamine. It's more potent than its mirror twin, [levoamphetamine](https://en.wikipedia.org/wiki/Levoamphetamine) , especially in stimulating dopamine and [norepinephrine](https://psychonautwiki.org/wiki/Noradrenaline) activity in the brain.

[Subjective effects](https://psychonautwiki.org/wiki/Subjective_effects) include [stimulation](https://psychonautwiki.org/wiki/Stimulation) , increased focus, [motivation enhancement](https://psychonautwiki.org/wiki/Motivation_enhancement) , [appetite suppression](https://psychonautwiki.org/wiki/Appetite_suppression) , [wakefulness](https://psychonautwiki.org/wiki/Wakefulness) , [thought acceleration](https://psychonautwiki.org/wiki/Thought_acceleration) , and [euphoria](https://psychonautwiki.org/wiki/Euphoria) . At lower to moderate doses, it can promote productivity, alertness, and sociability. However, higher doses may induce restlessness, anxiety, compulsive redosing, and over-stimulation. It is classified as a classical stimulant due to its ability to promote mental and physical arousal through increased catecholamine activity.

A notable property of dextroamphetamine is its high potential for abuse and rapid tolerance buildup. Repeated use over short periods can lead to diminished effects, compulsive use patterns, and a pronounced comedown characterized by [mental fatigue](https://en.wikipedia.org/wiki/Fatigue#Mental) , [irritability](https://psychonautwiki.org/wiki/Irritability) , and [anhedonia](https://psychonautwiki.org/wiki/Anhedonia) .

Recreational or street amphetamine is usually a racemic mix of both enantiomers, resulting in a broader and less focused effect profile compared to pure dextroamphetamine.

It is highly advised to use [harm reduction practices](https://psychonautwiki.org/wiki/Harm_reduction_practices) if using this substance.

## Chemistry

Dextroamphetamine is the dextrorotary [enantiomer](https://psychonautwiki.org/wiki/Enantiomer) of [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) , it is typically obtained via the chiral resolution of racemic amphetamine, but can also be synthesized via typically more envolved enantioselective syntheses.

Its physical properties are close to identical to those of (racemic) [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) or [levoamphetamine](/w/index.php?title=Levoamphetamine&action=edit&redlink=1) and tends to also be handled as its sulfate salt.

## History and culture

In 1937 Smith, Kline and French introduced tablets of the dextrorotary enantiomer of [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) (at that time sold as Benzedrine)under the tradename Dexedrine.

## Dangerous interactions

***Warning:*** *Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).*

*Always conduct independent research (e.g. [Google](https://www.google.com) , [DuckDuckGo](https://www.duckduckgo.com) , [PubMed](https://pubmed.ncbi.nlm.nih.gov/) ) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from [TripSit](https://combo.tripsit.me) .*

- **Alcohol** - Drinking alcohol on stimulants is considered risky because it reduces the sedative effects of the alcohol that the body uses to gauge drunkenness. This often leads to excessive drinking with greatly reduced inhibitions, increasing the risk of liver damage and increased dehydration. The effects of stimulants will also allow one to drink past a point where they might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less.
- **GHB** / **GBL** - Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the depressant effects of the GHB/GBL may overcome the user and cause respiratory arrest.
- **Opioids** - Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
- **Cocaine** - The rewarding effects of cocaine are mediated by DAT inhibition, and an increase of exocytosis of dopamine through the cell membrane. Amphetamine reverses the direction of DAT and the direction vesicular transports within the cell by a pH mediated mechanism of displacement, thus excludes the regular mechanism of dopamine release through means of exocytosis because the effects Na+/K+ ATPase are inhibited. You will find cardiac effects with the combination of cocaine and amphetamine due to a SERT mediated mechanism from the subsequent activation of 5-HT2B, which is an effect of serotonin-related valvulopathy. Amphetamines generally cause hypertension in models of abuse, and this combination can increase the chances of syncope due to turbulent blood flow during valve operation. The rewarding mechanisms of cocaine are reversed by administration of amphetamine.
- **Cannabis** - Stimulants increase [anxiety](https://psychonautwiki.org/wiki/Anxiety) levels and the risk of [thought loops](https://psychonautwiki.org/wiki/Thought_loops) and [paranoia](https://psychonautwiki.org/wiki/Paranoia) which can lead to negative experiences.
- **Caffeine** - This combination of stimulants is generally considered unnecessary and may increase strain on the heart, as well as potentially causing anxiety and physical discomfort.
- **Tramadol** - Tramadol and stimulants both increase the risk of seizures.
- **DXM** - Both substances raise heart rate, in extreme cases, panic attacks caused by these substances have led to more serious heart issues.
- **Ketamine** - Combining amphetamine and ketamine may result in psychoses that resemble schizophrenia, but not worse than the psychoses produced by either substance alone, but this is debatable. This is due to amphetamines ability to attenuated the disruption of working memory caused by ketamine. Amphetamine alone may result in grandiosity, paranoia, or somatic delusions with little to no effect on negative symptoms. Ketamine, however, will result in thought disorders, disruption of executive functioning, and delusions due to a modification of conception. These mechanisms are due to an increase of dopaminergic activity in the mesolimbic pathway caused by amphetamine due to its pharmacology effecting dopamine, and due to a disruption of dopaminergic functioning in the mesocortical pathways via NMDA antagonism effects of ketamine. Combining the two, you may expect mainly thought disorder along with positive symptoms.
- **PCP** - Increases risk of tachycardia, hypertension, and manic states.
- **Methoxetamine** - Increases risk of tachycardia, hypertension, and manic states.
- **Psychedelics** (e.g. ***[LSD](https://psychonautwiki.org/wiki/LSD) , [mescaline](https://psychonautwiki.org/wiki/Mescaline) , [psilocybin](https://psychonautwiki.org/wiki/Psilocybin)*** ) - Increases risk of [anxiety](https://psychonautwiki.org/wiki/Anxiety) , [paranoia](https://psychonautwiki.org/wiki/Paranoia) , and [thought loops](https://psychonautwiki.org/wiki/Thought_loops) . 
- **25x-NBOMe** - Amphetamines and NBOMes both provide considerable stimulation that when combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
- **2C-T-x** - Suspected of mild MAOI properties. May increase the risk of hypertensive crisis.
- **5-MeO-xxT** - Suspected of mild MAOI properties. May increase the risk of hypertensive crisis.
- **DOx**
- **aMT** - aMT has MAOI properties which may interact unfavorably with amphetamines.
- **MAOIs** - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with amphetamine can lead to hypertensive crises.

## Legal status

Internationally, [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) (and its isomers **dextroamphetamine** and [levoamphetamine](/w/index.php?title=Levoamphetamine&action=edit&redlink=1) ) are Schedule II controlled substances under the United Nations 1971 Convention on Psychotropic Substances.

- **Australia** : Dextroamphetamine is a Schedule 8 controlled substance.
- **Austria** : Dextroamphetamine is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
- **Brazil** : Dextroamphetamine is a Class A3 psychoactice substance.
- **Canada** : Dextroamphetamine is a Schedule I drug in Canada.
- **France** : Dextroamphetamine is scheduled as a "stupéfiant", i.e. a recognized drug of abuse, as an isomer of amphetamine. It is illegal to possess, buy, sell or manufacture. It is not prescriptible
- **Germany** : Dextroamphetamine is controlled under Anlage III BtMG ( *Narcotics Act, Schedule III* ). It can only be prescribed on a narcotic prescription form.
- **The Netherlands** : Dextroamphetamine is a List I controlled substance.
- **South Korea** : Dextromphetamine is prohibited even for medical use in South Korea in compliance with the United Nations Convention on Psychotropic Substances.
- **Sweden** : Dextroamphetamine is a List II controlled substance. It can only be prescribed by doctors with specialist competence in child and adolescent psychiatry, psychiatry, forensic psychiatry, neurology or child and adolescent neurology with habilitation.
- **United Kingdom** : [Amphetamine](https://psychonautwiki.org/wiki/Amphetamine) is a Class B drug in the United Kingdom, without any clarification about isomers.
- **United States** : [Amphetamine](https://psychonautwiki.org/wiki/Amphetamine) is a Schedule IIN controlled substance in the United States, citing several **dextroamphetamine** prescription drugs as examples.

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Stimulant](https://psychonautwiki.org/wiki/Stimulant)
- [Amphetamine](https://psychonautwiki.org/wiki/Amphetamine)
- [Enantiomers](https://psychonautwiki.org/wiki/Enantiomers)
- [Levoamphetamine](/w/index.php?title=Levoamphetamine&action=edit&redlink=1)
- [Amphetamines](https://psychonautwiki.org/wiki/Amphetamines)

## External links

- [Dextroamphetamine (Wikipedia)](http://en.wikipedia.org/wiki/Dextroamphetamine)
- [Dextroamphetamine (Erowid Vault)](https://erowid.org//chemicals/amphetamines/amphetamines.shtml)
- [Dextroamphetamine (DrugBank)](https://go.drugbank.com/drugs/DB01576)
- [Dextroamphetamine (Drugs.com)](https://www.drugs.com/mtm/dextroamphetamine.html)

## References
1. ↑ " [chemeurope.com - Amphetamine](https://www.chemeurope.com/en/encyclopedia/Amphetamine.html)
2. ↑ " [Drugbank - Amphetamine](https://go.drugbank.com/drugs/DB00182)
3. ↑ Greenwald, M. K., Lundahl, L. H., Steinmiller, C. L. (December 2010).["Sustained Release d-Amphetamine Reduces Cocaine but not 'Speedball'-Seeking in Buprenorphine-Maintained Volunteers: A Test of Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers"](http://www.nature.com/articles/npp2010175).*Neuropsychopharmacology*.**35**(13): 2624–2637.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1038/npp.2010.175](//doi.org/10.1038%2Fnpp.2010.175).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0893-133X](//www.worldcat.org/issn/0893-133X).
4. ↑ Siciliano, C. A., Saha, K., Calipari, E. S., Fordahl, S. C., Chen, R., Khoshbouei, H., Jones, S. R. (10 January 2018).["Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation"](https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.2604-17.2017).*The Journal of Neuroscience*.**38**(2): 484–497.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1523/JNEUROSCI.2604-17.2017](//doi.org/10.1523%2FJNEUROSCI.2604-17.2017).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0270-6474](//www.worldcat.org/issn/0270-6474).
5. ↑ Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., D’Souza, D. C. (1 September 2005).["Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function"](http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archpsyc.62.9.985).*Archives of General Psychiatry*.**62**(9): 985.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1001/archpsyc.62.9.985](//doi.org/10.1001%2Farchpsyc.62.9.985).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0003-990X](//www.worldcat.org/issn/0003-990X).
6. ↑ ["CONVENTION ON PSYCHOTROPIC SUBSTANCES 1971"](http://www.emcdda.europa.eu/system/files/attachments/10451/convention_1971_en.pdf)(PDF). United Nations. Retrieved December 19, 2019.
7. ↑ ["POISONS STANDARD DECEMBER 2019"](https://www.legislation.gov.au/Details/F2019L01471). Office of Parliamentary Counsel. Retrieved December 19, 2019.
8. ↑ [https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011053](https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011053)
9. ↑ [https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992](https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992)
10. ↑ Controlled Drugs and Substances Act | [http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-24.html#h-28](http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-24.html#h-28)
11. ↑ [Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants](https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/)
12. ↑ ["Anlage III BtMG"](https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 19, 2019.
13. ↑ [https://wetten.overheid.nl/BWBR0001941/2009-07-01](https://wetten.overheid.nl/BWBR0001941/2009-07-01)
14. ↑ [https://web.archive.org/web/20160331074842/https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=VI-16&chapter=6&lang=en](https://web.archive.org/web/20160331074842/https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=VI-16&chapter=6&lang=en)
15. ↑ [Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika](https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/hslf-fs/lvfs-2011-10-konsoliderad2.pdf)
16. ↑ [Läkemedelsverkets föreskrifter (HSLF-FS 2017:74) om begränsningar av förordnande och utlämnande av vissa läkemedel](https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/hslf-fs/hslf-fs-2017-74-konsoliderad.pdf)
17. ↑ [Misuse of Drugs Act 1971](https://www.legislation.gov.uk/ukpga/1971/38/schedule/2)
18. ↑ [https://www.deadiversion.usdoj.gov/schedules/](https://www.deadiversion.usdoj.gov/schedules/)NewPP limit report Cached time: 20251218075322 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.045 seconds CPU time usage: 0.219 seconds Real time usage: 0.428 seconds Preprocessor visited node count: 1608/1000000 Post‐expand include size: 96482/2097152 bytes Template argument size: 2796/2097152 bytes Highest expansion depth: 9/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 16325/5000000 bytes Lua time usage: 0.150/7 seconds Lua virtual size: 7.21 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 22Transclusion expansion time report (%,ms,calls,template) 100.00% 337.243 1 -total 75.60% 254.970 1 Template:Reflist 37.02% 124.841 4 Template:Citation 21.71% 73.205 3 Template:Cite_journal 19.00% 64.079 1 Template:SubstanceBox/Dextroamphetamine 17.62% 59.410 1 Template:SubstanceBox 12.09% 40.763 3 Template:Cite_web 1.22% 4.128 1 Template:SummarySheet 1.21% 4.092 2 Template:ISBDosageChart 1.11% 3.741 1 Template:Preamble/SubstanceSafeUse`,
  "saferparty": `# Dexamphetamine
*Source: [SaferParty](https://saferparty.ch) - Drug Checking Service (Switzerland)*

## Effects
Taking dexamphetamine increases the concentration of the nerve messengers dopamine and noradrenaline. When prescribed for ADHD, the substance is supposed to act as a filter for incoming stimuli and alleviate symptoms such as distractibility, attention deficit disorder, disorganisation and impulsivity.
However, due to their stimulating, energising and euphoric properties, dexamphetamine and Adderall® are also used as recreational drugs or to enhance performance

## Risks

### Short-term Risks
When prescribed by a doctor or used as directed, sleep disturbances and irritability can often occur. The most common adverse effects include: Cardiovascular and arrhythmias, rapid pulse, high blood pressure, lack of appetite, nausea, dry mouth, dizziness, insomnia, anxiety and/or joint pain.
In overdose, it can cause, among other things, hallucinations, muscle twitching, panic, aggressiveness and/or restlessness.

### Long-term Risks
When used therapeutically, it is assumed that no dependence will develop. When abusing higher doses over a longer period of time, psychological dependence may develop. With abrupt discontinuation, withdrawal symptoms such as lethargy, apathy, depression and paranoia may occur.

## Safer Use
- If possible, do not consume amphetamine-containing substances intravenously. Due to the substances contained in the tablets, embolism (blockage of vessels in the lungs or brain) can occur.
`,
  "tripsit-factsheets": `# Dexedrine
*Source: https://tripbot.tripsit.me/api/tripsit/getDrug/dexedrine*

## Classification
- **Categories:** stimulant, habit-forming, common
- **Also known as:** dextroamphetamine, dexamfetamine

## Dosage

### Oral
- **Common:** 10-20mg
- **Light:** 5-10mg
- **Strong:** 20-30mg.

## Duration
- **Onset:** 20-60 minutes
- **Duration:** 3-6 hours
- **After Effects:** 2-24 hours
`,
  "wikipedia": `# Dextroamphetamine
*Source: https://en.wikipedia.org/wiki/Dextroamphetamine*

Dextroamphetamine is a central nervous system (CNS) stimulant and enantiomer of amphetamine that is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.  It is also used illicitly to enhance cognitive and athletic performance, and recreationally as an aphrodisiac and euphoriant. Dextroamphetamine is generally regarded as the prototypical stimulant.
The amphetamine molecule exists as two enantiomers, levoamphetamine and dextroamphetamine. Dextroamphetamine is the dextrorotatory, or 'right-handed', enantiomer and exhibits more pronounced effects on the central nervous system than levoamphetamine. Pharmaceutical dextroamphetamine sulfate is available as both a brand name and generic drug in a variety of dosage forms. Dextroamphetamine is sometimes prescribed as the inactive prodrug lisdexamfetamine.
Side effects of dextroamphetamine at therapeutic doses include elevated mood, decreased appetite, dry mouth, excessive grinding of the teeth, headache, increased heart rate, increased wakefulness or insomnia, anxiety, and irritability, among others. At excessive doses, psychosis (i.e., hallucinations, delusions), addiction, and rapid muscle breakdown may occur. However, for individuals with pre-existing psychotic disorders, there may be a risk of psychosis even at therapeutic doses.
Dextroamphetamine, like other amphetamines, elicits its stimulating effects via several distinct actions: it inhibits or reverses the transporter proteins for the monoamine neurotransmitters (namely the serotonin, norepinephrine and dopamine transporters) either via trace amine-associated receptor 1 (TAAR1) or in a TAAR1 independent fashion when there are high cytosolic concentrations of the monoamine neurotransmitters and it releases these neurotransmitters from synaptic vesicles via vesicular monoamine transporter 2 (VMAT2). It also shares many chemical and pharmacological properties with human trace amines, particularly phenethylamine and N-methylphenethylamine, the latter being an isomer of amphetamine produced within the human body. It is available as a generic medication. In 2022, mixed amphetamine salts (Adderall) was the 14th most commonly prescribed medication in the United States, with more than 34 million prescriptions.

## Uses

### Medical

Dextroamphetamine is used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is sometimes prescribed off-label for depression and obesity.

#### ADHD

Long-term amphetamine exposure at sufficiently high doses in some animal species is known to produce abnormal dopamine system development or nerve damage, but, in humans with ADHD, long-term use of pharmaceutical amphetamines at therapeutic doses appears to improve brain development and nerve growth. Reviews of magnetic resonance imaging (MRI) studies suggest that long-term treatment with amphetamine decreases abnormalities in brain structure and function found in subjects with ADHD, and improves function in several parts of the brain, such as the right caudate nucleus of the basal ganglia.
Reviews of clinical stimulant research have established the safety and effectiveness of long-term continuous amphetamine use for the treatment of ADHD. Randomized controlled trials of continuous stimulant therapy for the treatment of ADHD spanning 2 years have demonstrated treatment effectiveness and safety. Two reviews have indicated that long-term continuous stimulant therapy for ADHD is effective for reducing the core symptoms of ADHD (i.e., hyperactivity, inattention, and impulsivity), enhancing quality of life and academic achievement, and producing improvements in a large number of functional outcomes across 9 categories of outcomes related to academics, antisocial behavior, driving, non-medicinal drug use, obesity, occupation, self-esteem, service use (i.e., academic, occupational, health, financial, and legal services), and social function. Additionally, a 2024 meta-analytic systematic review reported moderate improvements in quality of life when amphetamine treatment is used for ADHD. One review highlighted a nine-month randomized controlled trial of amphetamine treatment for ADHD in children that found an average increase of 4.5 IQ points, continued increases in attention, and continued decreases in disruptive behaviors and hyperactivity. Another review indicated that, based upon the longest follow-up studies conducted to date, lifetime stimulant therapy that begins during childhood is continuously effective for controlling ADHD symptoms and reduces the risk of developing a substance use disorder as an adult. 
Models of ADHD suggest that it is associated with functional impairments in some of the brain's neurotransmitter systems; these functional impairments involve impaired dopamine neurotransmission in the mesocorticolimbic projection and norepinephrine neurotransmission in the noradrenergic projections from the locus coeruleus to the prefrontal cortex. Stimulants like methylphenidate and amphetamine are effective in treating ADHD because they increase neurotransmitter activity in these systems. Approximately 80% of those who use these stimulants see improvements in ADHD symptoms. Children with ADHD who use stimulant medications generally have better relationships with peers and family members, perform better in school, are less distractible and impulsive, and have longer attention spans. The Cochrane reviews on the treatment of ADHD in children, adolescents, and adults with pharmaceutical amphetamines stated that short-term studies have demonstrated that these drugs decrease the severity of symptoms, but they have higher discontinuation rates than non-stimulant medications due to their adverse side effects. However, a 2025 meta-analytic systematic review of 113 randomized controlled trials found that stimulant medications were the only intervention with robust short-term efficacy, and were associated with lower all-cause treatment discontinuation rates than non-stimulant medications (e.g., atomoxetine). A Cochrane review on the treatment of ADHD in children with tic disorders such as Tourette syndrome indicated that stimulants in general do not make tics worse, but high doses of dextroamphetamine could exacerbate tics in some individuals.

#### Narcolepsy

Narcolepsy is a chronic sleep-wake disorder that is associated with excessive daytime sleepiness, cataplexy, and sleep paralysis. Patients with narcolepsy are diagnosed as either type 1 or type 2, with only the former presenting cataplexy symptoms. Type 1 narcolepsy results from the loss of approximately 70,000 orexin-releasing neurons in the lateral hypothalamus, leading to significantly reduced cerebrospinal orexin levels; this reduction is a diagnostic biomarker for type 1 narcolepsy. Lateral hypothalamic orexin neurons innervate every component of the ascending reticular activating system (ARAS), which includes noradrenergic, dopaminergic, histaminergic, and serotonergic nuclei that promote wakefulness.
Amphetamine's therapeutic mode of action in narcolepsy primarily involves increasing monoamine neurotransmitter activity in the ARAS. This includes noradrenergic neurons in the locus coeruleus, dopaminergic neurons in the ventral tegmental area, histaminergic neurons in the tuberomammillary nucleus, and serotonergic neurons in the dorsal raphe nucleus. Dextroamphetamine, the more dopaminergic enantiomer of amphetamine, is particularly effective at promoting wakefulness because dopamine release has the greatest influence on cortical activation and cognitive arousal, relative to other monoamines. In contrast, levoamphetamine may have a greater effect on cataplexy, a symptom more sensitive to the effects of norepinephrine and serotonin. Noradrenergic and serotonergic nuclei in the ARAS are involved in the regulation of the REM sleep cycle and function as "REM-off" cells, with amphetamine's effect on norepinephrine and serotonin contributing to the suppression of REM sleep and a possible reduction of cataplexy at high doses.
The American Academy of Sleep Medicine (AASM) 2021 clinical practice guideline conditionally recommends dextroamphetamine for the treatment of both type 1 and type 2 narcolepsy. Treatment with pharmaceutical amphetamines is generally less preferred relative to other stimulants (e.g., modafinil) and is considered a third-line treatment option. Medical reviews indicate that amphetamine is safe and effective for the treatment of narcolepsy. Amphetamine appears to be most effective at improving symptoms associated with hypersomnolence, with three reviews finding clinically significant reductions in daytime sleepiness in patients with narcolepsy. Additionally, these reviews suggest that amphetamine may dose-dependently improve cataplexy symptoms. However, the quality of evidence for these findings is low and is consequently reflected in the AASM's conditional recommendation for dextroamphetamine as a treatment option for narcolepsy.

### Enhancing performance

#### Cognitive performance

In 2015, a systematic review and a meta-analysis of high quality clinical trials found that, when used at low (therapeutic) doses, amphetamine produces modest yet unambiguous improvements in cognition, including working memory, long-term episodic memory, inhibitory control, and some aspects of attention, in normal healthy adults; these cognition-enhancing effects of amphetamine are known to be partially mediated through the indirect activation of both dopamine D1 receptor and α2-adrenergic receptor in the prefrontal cortex. A systematic review from 2014 found that low doses of amphetamine also improve memory consolidation, in turn leading to improved recall of information. Therapeutic doses of amphetamine also enhance cortical network efficiency, an effect which mediates improvements in working memory in all individuals. Amphetamine and other ADHD stimulants also improve task saliency (motivation to perform a task) and increase arousal (wakefulness), in turn promoting goal-directed behavior. Stimulants such as amphetamine can improve performance on difficult and boring tasks and are used by some students as a study and test-taking aid. Based upon studies of self-reported illicit stimulant use, 5–35% of college students use diverted ADHD stimulants, which are primarily used for enhancement of academic performance rather than as recreational drugs. However, high amphetamine doses that are above the therapeutic range can interfere with working memory and other aspects of cognitive control.

#### Physical performance

Amphetamine is used by some athletes for its psychological and athletic performance-enhancing effects, such as increased endurance and alertness; however, non-medical amphetamine use is prohibited at sporting events that are regulated by collegiate, national, and international anti-doping agencies. In healthy people at oral therapeutic doses, amphetamine has been shown to increase muscle strength, acceleration, athletic performance in anaerobic conditions, and endurance (i.e., it delays the onset of fatigue), while improving reaction time. Amphetamine improves endurance and reaction time primarily through reuptake inhibition and release of dopamine in the central nervous system. Amphetamine and other dopaminergic drugs also increase power output at fixed levels of perceived exertion by overriding a "safety switch", allowing the core temperature limit to increase in order to access a reserve capacity that is normally off-limits. At therapeutic doses, the adverse effects of amphetamine do not impede athletic performance; however, at much higher doses, amphetamine can induce effects that severely impair performance, such as rapid muscle breakdown and elevated body temperature.

### Recreational

Dextroamphetamine is also used recreationally as a euphoriant and aphrodisiac, and, like other amphetamines, is used as a club drug for its energetic and euphoric high. Dextroamphetamine is considered to have a high potential for misuse in a recreational manner since individuals typically report feeling euphoric, more alert, and more energetic after taking the drug. Dextroamphetamine's dopaminergic (rewarding) properties affect the mesocorticolimbic circuit; a group of neural structures responsible for incentive salience (i.e., "wanting"; desire or craving for a reward and motivation), positive reinforcement and positively-valenced emotions, particularly ones involving pleasure. Large recreational doses of dextroamphetamine may produce dextroamphetamine overdose. Recreational users sometimes open dexedrine capsules and crush the contents in order to insufflate (snort) it or subsequently dissolve it in water and inject it. Immediate-release formulations have higher potential for abuse via insufflation (snorting) or intravenous injection due to a more favorable pharmacokinetic profile and easy crushability (especially tablets).
The reason for using crushed spansules for insufflation and injection methods is evidently due to the instant-release forms of the drug seen in tablet preparations often containing a sizable amount of inactive binders and fillers alongside the active d-amphetamine, such as dextrose. Injection into the bloodstream can be dangerous because insoluble fillers within the tablets can block small blood vessels. Chronic overuse of dextroamphetamine can lead to severe drug dependence, resulting in withdrawal symptoms when drug use stops.

## Contraindications

According to the International Programme on Chemical Safety (IPCS) and the U.S. Food and Drug Administration (FDA), amphetamine is contraindicated in people with a history of drug abuse, cardiovascular disease, severe agitation, or severe anxiety. It is also contraindicated in individuals with advanced arteriosclerosis (hardening of the arteries), glaucoma (increased eye pressure), hyperthyroidism (excessive production of thyroid hormone), or moderate to severe hypertension. These agencies indicate that people who have experienced allergic reactions to other stimulants or who are taking monoamine oxidase inhibitors (MAOIs) should not take amphetamine, although safe concurrent use of amphetamine and monoamine oxidase inhibitors has been documented. These agencies also state that anyone with anorexia nervosa, bipolar disorder, depression, hypertension, liver or kidney problems, mania, psychosis, Raynaud's phenomenon, seizures, thyroid problems, tics, or Tourette syndrome should monitor their symptoms while taking amphetamine. Evidence from human studies indicates that therapeutic amphetamine use does not cause developmental abnormalities in the fetus or newborns (i.e., it is not a human teratogen), but amphetamine abuse does pose risks to the fetus. Amphetamine has also been shown to pass into breast milk, so the IPCS and the FDA advise mothers to avoid breastfeeding when using it. Due to the potential for reversible growth impairments, the FDA advises monitoring the height and weight of children and adolescents prescribed an amphetamine pharmaceutical.

## Adverse effects

### Physical

Cardiovascular side effects can include hypertension or hypotension from a vasovagal response, Raynaud's phenomenon (reduced blood flow to the hands and feet), and tachycardia (increased heart rate). Sexual side effects in males may include erectile dysfunction, frequent erections, or prolonged erections. Gastrointestinal side effects may include abdominal pain, constipation, diarrhea, and nausea. Other potential physical side effects include appetite loss, blurred vision, dry mouth, excessive grinding of the teeth, nosebleed, profuse sweating, rhinitis medicamentosa (drug-induced nasal congestion), reduced seizure threshold, tics (a type of movement disorder), and weight loss. Dangerous physical side effects are rare at typical pharmaceutical doses.
Amphetamine stimulates the medullary respiratory centers, producing faster and deeper breaths. In a normal person at therapeutic doses, this effect is usually not noticeable, but when respiration is already compromised, it may be evident. Amphetamine also induces contraction in the urinary bladder sphincter, the muscle which controls urination, which can result in difficulty urinating. This effect can be useful in treating bed wetting and loss of bladder control. The effects of amphetamine on the gastrointestinal tract are unpredictable. If intestinal activity is high, amphetamine may reduce gastrointestinal motility (the rate at which content moves through the digestive system); however, amphetamine may increase motility when the smooth muscle of the tract is relaxed. Amphetamine also has a slight analgesic effect and can enhance the pain relieving effects of opioids.
FDA-commissioned studies from 2011 indicate that in children, young adults, and adults there is no association between serious adverse cardiovascular events (sudden death, heart attack, and stroke) and the medical use of amphetamine or other ADHD stimulants. These findings were subsequently corroborated by a 2022 meta-analysis that sampled nearly four million participants, which found no association between therapeutic use of amphetamine and the development of cardiovascular disease in any age group. However, amphetamine pharmaceuticals are contraindicated in individuals with preexisting cardiovascular disease.

### Psychological

At normal therapeutic doses, the most common psychological side effects of amphetamine include increased alertness, apprehension, concentration, initiative, self-confidence and sociability, mood swings (elated mood followed by mildly depressed mood), insomnia or wakefulness, and decreased sense of fatigue. Less common side effects include anxiety, change in libido, grandiosity, irritability, repetitive or obsessive behaviors, and restlessness; these effects depend on the user's personality and current mental state. Amphetamine psychosis (e.g., delusions and paranoia) can occur in heavy users. Although very rare, this psychosis can also occur at therapeutic doses during long-term therapy. According to the FDA, "there is no systematic evidence" that stimulants produce aggressive behavior or hostility.
Amphetamine has also been shown to produce a conditioned place preference in humans taking therapeutic doses, meaning that individuals acquire a preference for spending time in places where they have previously used amphetamine.

### Reinforcement disorders

#### Addiction

Addiction is a serious risk with heavy recreational amphetamine use, but is unlikely to occur from long-term medical use at therapeutic doses; in fact, lifetime stimulant therapy for ADHD that begins during childhood reduces the risk of developing substance use disorders as an adult.  Pathological overactivation of the mesolimbic pathway, a dopamine pathway that connects the ventral tegmental area to the nucleus accumbens, plays a central role in amphetamine addiction. Individuals who frequently self-administer high doses of amphetamine have a high risk of developing an amphetamine addiction, since chronic use at high doses gradually increases the level of accumbal ΔFosB, a "molecular switch" and "master control protein" for addiction. Once nucleus accumbens ΔFosB is sufficiently overexpressed, it begins to increase the severity of addictive behavior (i.e., compulsive drug-seeking) with further increases in its expression. While there are currently no effective drugs for treating amphetamine addiction, regularly engaging in sustained aerobic exercise appears to reduce the risk of developing such an addiction. Exercise therapy improves clinical treatment outcomes and may be used as an adjunct therapy with behavioral therapies for addiction.

#### Biomolecular mechanisms

Chronic use of amphetamine at excessive doses causes alterations in gene expression in the mesocorticolimbic projection, which arise through transcriptional and epigenetic mechanisms. The most important transcription factors that produce these alterations are Delta FBJ murine osteosarcoma viral oncogene homolog B (ΔFosB), cAMP response element binding protein (CREB), and nuclear factor-kappa B (NF-κB). ΔFosB is the most significant biomolecular mechanism in addiction because ΔFosB overexpression (i.e., an abnormally high level of gene expression which produces a pronounced gene-related phenotype) in the D1-type medium spiny neurons in the nucleus accumbens is necessary and sufficient for many of the neural adaptations and regulates multiple behavioral effects (e.g., reward sensitization and escalating drug self-administration) involved in addiction. Once ΔFosB is sufficiently overexpressed, it induces an addictive state that becomes increasingly more severe with further increases in ΔFosB expression. It has been implicated in addictions to alcohol, cannabinoids, cocaine, methylphenidate, nicotine, opioids, phencyclidine, propofol, and substituted amphetamines, among others.
ΔJunD, a transcription factor, and G9a, a histone methyltransferase enzyme, both oppose the function of ΔFosB and inhibit increases in its expression. Sufficiently overexpressing ΔJunD in the nucleus accumbens with viral vectors can completely block many of the neural and behavioral alterations seen in chronic drug abuse (i.e., the alterations mediated by ΔFosB). Similarly, accumbal G9a hyperexpression results in markedly increased histone 3 lysine residue 9 dimethylation (H3K9me2) and blocks the induction of ΔFosB-mediated neural and behavioral plasticity by chronic drug use, which occurs via H3K9me2-mediated repression of transcription factors for ΔFosB and H3K9me2-mediated repression of various ΔFosB transcriptional targets (e.g., CDK5). ΔFosB also plays an important role in regulating behavioral responses to natural rewards, such as palatable food, sex, and exercise. Since both natural rewards and addictive drugs induce the expression of ΔFosB (i.e., they cause the brain to produce more of it), chronic acquisition of these rewards can result in a similar pathological state of addiction. Consequently, ΔFosB is the most significant factor involved in both amphetamine addiction and amphetamine-induced sexual addictions, which are compulsive sexual behaviors that result from excessive sexual activity and amphetamine use. These sexual addictions are associated with a dopamine dysregulation syndrome which occurs in some patients taking dopaminergic drugs.
The effects of amphetamine on gene regulation are both dose- and route-dependent. Most of the research on gene regulation and addiction is based upon animal studies with intravenous amphetamine administration at very high doses. The few studies that have used equivalent (weight-adjusted) human therapeutic doses and oral administration show that these changes, if they occur, are relatively minor. This suggests that medical use of amphetamine does not significantly affect gene regulation.

##### Pharmacological treatments

As of December 2019, there is no effective pharmacotherapy for amphetamine addiction. Reviews from 2015 and 2016 indicated that TAAR1-selective agonists have significant therapeutic potential as a treatment for psychostimulant addictions; however, as of February 2016, the only compounds which are known to function as TAAR1-selective agonists are experimental drugs. Amphetamine addiction is largely mediated through increased activation of dopamine receptors and co-localized NMDA receptors in the nucleus accumbens; magnesium ions inhibit NMDA receptors by blocking the receptor calcium channel. One review suggested that, based upon animal testing, pathological (addiction-inducing) psychostimulant use significantly reduces the level of intracellular magnesium throughout the brain. Supplemental magnesium treatment has been shown to reduce amphetamine self-administration (i.e., doses given to oneself) in humans, but it is not an effective monotherapy for amphetamine addiction.
A systematic review and meta-analysis from 2019 assessed the efficacy of 17 different pharmacotherapies used in randomized controlled trials (RCTs) for amphetamine and methamphetamine addiction; it found only low-strength evidence that methylphenidate might reduce amphetamine or methamphetamine self-administration. There was low- to moderate-strength evidence of no benefit for most of the other medications used in RCTs, which included antidepressants (bupropion, mirtazapine, sertraline), antipsychotics (aripiprazole), anticonvulsants (topiramate, baclofen, gabapentin), naltrexone, varenicline, citicoline, ondansetron, prometa, riluzole, atomoxetine, dextroamphetamine, and modafinil.

##### Behavioral treatments

A 2018 systematic review and network meta-analysis of 50 trials involving 12 different psychosocial interventions for amphetamine, methamphetamine, or cocaine addiction found that combination therapy with both contingency management and community reinforcement approach had the highest efficacy (i.e., abstinence rate) and acceptability (i.e., lowest dropout rate). Other treatment modalities examined in the analysis included monotherapy with contingency management or community reinforcement approach, cognitive behavioral therapy, 12-step programs, non-contingent reward-based therapies, psychodynamic therapy, and other combination therapies involving these.
Additionally, research on the neurobiological effects of physical exercise suggests that daily aerobic exercise, especially endurance exercise (e.g., marathon running), prevents the development of drug addiction and is an effective adjunct therapy (i.e., a supplemental treatment) for amphetamine addiction. Exercise leads to better treatment outcomes when used as an adjunct treatment, particularly for psychostimulant addictions. In particular, aerobic exercise decreases psychostimulant self-administration, reduces the reinstatement (i.e., relapse) of drug-seeking, and induces increased dopamine receptor D2 (DRD2) density in the striatum. This is the opposite of pathological stimulant use, which induces decreased striatal DRD2 density. One review noted that exercise may also prevent the development of a drug addiction by altering ΔFosB or c-Fos immunoreactivity in the striatum or other parts of the reward system.

#### Dependence and withdrawal

Drug tolerance develops rapidly in amphetamine abuse (i.e., recreational amphetamine use), so periods of extended abuse require increasingly larger doses of the drug in order to achieve the same effect.
According to a Cochrane review on withdrawal in individuals who compulsively use amphetamine and methamphetamine, "when chronic heavy users abruptly discontinue amphetamine use, many report a time-limited withdrawal syndrome that occurs within 24 hours of their last dose." This review noted that withdrawal symptoms in chronic, high-dose users are frequent, occurring in roughly 88% of cases, and persist for 3–4 weeks with a marked "crash" phase occurring during the first week. Amphetamine withdrawal symptoms can include anxiety, drug craving, depressed mood, fatigue, increased appetite, increased movement or decreased movement, lack of motivation, sleeplessness or sleepiness, and lucid dreams. The review indicated that the severity of withdrawal symptoms is positively correlated with the age of the individual and the extent of their dependence.
According to a 2025 review, the discontinuation of amphetamine at therapeutic doses does not typically result in withdrawal symptoms. Discontinuation may unmask or cause a rebound of ADHD symptoms due to the cessation of treatment-related drug effects. In cases where mild withdrawal symptoms do occur, they can be avoided by tapering the dose. Unlike amphetamine abuse, where drug tolerance necessitates escalating doses to achieve the same effect, tolerance to clinically relevant doses of amphetamine plateaus after the initial titration period, and "drug holidays" (i.e., temporary treatment discontinuation) are not required to prevent the development of tolerance.

## Overdose

An amphetamine overdose can lead to many different symptoms, but is rarely fatal with appropriate care. The severity of overdose symptoms increases with dosage and decreases with drug tolerance to amphetamine. Tolerant individuals have been known to take as much as 5 grams of amphetamine in a day, which is roughly 100 times the maximum daily therapeutic dose. Symptoms of a moderate and extremely large overdose are listed below; fatal amphetamine poisoning usually also involves convulsions and coma. In 2013, overdose on amphetamine, methamphetamine, and other compounds implicated in an "amphetamine use disorder" resulted in an estimated 3,788 deaths worldwide (3,425–4,145 deaths, 95% confidence).

### Toxicity

In rodents and primates, sufficiently high doses of amphetamine cause dopaminergic neurotoxicity, or damage to dopamine neurons, which is characterized by dopamine terminal degeneration and reduced transporter and receptor function. There is no evidence that amphetamine is directly neurotoxic in humans. However, large doses of amphetamine may indirectly cause dopaminergic neurotoxicity as a result of hyperpyrexia, the excessive formation of reactive oxygen species, and increased autoxidation of dopamine. Animal models of neurotoxicity from high-dose amphetamine exposure indicate that the occurrence of hyperpyrexia (i.e., core body temperature ≥ 40 °C) is necessary for the development of amphetamine-induced neurotoxicity. Prolonged elevations of brain temperature above 40 °C likely promote the development of amphetamine-induced neurotoxicity in laboratory animals by facilitating the production of reactive oxygen species, disrupting cellular protein function, and transiently increasing blood–brain barrier permeability.

### Psychosis

An amphetamine overdose can result in a stimulant psychosis that may involve a variety of symptoms, such as delusions and paranoia. A Cochrane review on treatment for amphetamine, dextroamphetamine, and methamphetamine psychosis states that about 5–15% of users fail to recover completely. According to the same review, there is at least one trial that shows antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis. Psychosis rarely arises from therapeutic use.

## Interactions

Many types of substances are known to interact with amphetamine, resulting in altered drug action or metabolism of amphetamine, the interacting substance, or both. Inhibitors of the enzymes that metabolize amphetamine (e.g., CYP2D6 and FMO3) will prolong its elimination half-life, meaning that its effects will last longer. Amphetamine also interacts with MAOIs, particularly monoamine oxidase A inhibitors, since both MAOIs and amphetamine increase plasma catecholamines (i.e., norepinephrine and dopamine); therefore, concurrent use of both is dangerous. Amphetamine modulates the activity of most psychoactive drugs. In particular, amphetamine may decrease the effects of sedatives and depressants and increase the effects of stimulants and antidepressants. Amphetamine may also decrease the effects of antihypertensives and antipsychotics due to its effects on blood pressure and dopamine respectively. Zinc supplementation may reduce the minimum effective dose of amphetamine when it is used for the treatment of ADHD. Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have been found to reduce the stimulant, euphoriant, and sympathomimetic effects of dextroamphetamine in humans.

## Pharmacology

### Pharmacodynamics

Amphetamine and its enantiomers have been identified as potent full agonists of trace amine-associated receptor 1 (TAAR1), a GPCR, discovered in 2001, that is important for regulation of monoaminergic systems in the brain. Activation of TAAR1 increases cAMP production via adenylyl cyclase activation and inhibits the function of the dopamine transporter, norepinephrine transporter, and serotonin transporter, as well as inducing the release of these monoamine neurotransmitters (effluxion). Amphetamine enantiomers are also substrates for a specific neuronal synaptic vesicle uptake transporter called VMAT2. When amphetamine is taken up by VMAT2, the vesicle releases (effluxes) dopamine, norepinephrine, and serotonin, among other monoamines, into the cytosol in exchange.
Dextroamphetamine (the dextrorotary enantiomer) and levoamphetamine (the levorotary enantiomer) have identical pharmacodynamics, but their binding affinities to their biomolecular targets vary. Dextroamphetamine is a more potent agonist of TAAR1 than levoamphetamine. Consequently, dextroamphetamine produces roughly three to four times more central nervous system (CNS) stimulation than levoamphetamine; however, levoamphetamine has slightly greater cardiovascular and peripheral effects.

### Related endogenous compounds

Amphetamine has a very similar structure and function to the endogenous trace amines, which are naturally occurring neuromodulator molecules produced in the human body and brain. Among this group, the most closely related compounds are phenethylamine, the parent compound of amphetamine, and N-methylphenethylamine, a structural isomer of amphetamine (i.e., it has an identical molecular formula). In humans, phenethylamine is produced directly from L-phenylalanine by the aromatic amino acid decarboxylase (AADC) enzyme, which converts L-DOPA into dopamine as well. In turn, N-methylphenethylamine is metabolized from phenethylamine by phenylethanolamine N-methyltransferase, the same enzyme that metabolizes norepinephrine into epinephrine. Like amphetamine, both phenethylamine and N-methylphenethylamine regulate monoamine neurotransmission via TAAR1; unlike amphetamine, both of these substances are broken down by monoamine oxidase B, and therefore have a shorter half-life than amphetamine.

### Pharmacokinetics

The oral bioavailability of amphetamine varies with gastrointestinal pH; it is well absorbed from the gut, and bioavailability is typically 90%. Amphetamine is a weak base with a pKa of 9.9; consequently, when the pH is basic, more of the drug is in its lipid soluble free base form, and more is absorbed through the lipid-rich cell membranes of the gut epithelium. Conversely, an acidic pH means the drug is predominantly in a water-soluble cationic (salt) form, and less is absorbed. Approximately 20% of amphetamine circulating in the bloodstream is bound to plasma proteins. Following absorption, amphetamine readily distributes into most tissues in the body, with high concentrations occurring in cerebrospinal fluid and brain tissue.
The half-lives of amphetamine enantiomers differ and vary with urine pH. At normal urine pH, the half-lives of dextroamphetamine and levoamphetamine are 9–11 hours and 11–14 hours, respectively. Highly acidic urine will reduce the enantiomer half-lives to 7 hours; highly alkaline urine will increase the half-lives up to 34 hours. The immediate-release and extended release variants of salts of both isomers reach peak plasma concentrations at 3 hours and 7 hours post-dose respectively. Amphetamine is eliminated via the kidneys, with 30–40% of the drug being excreted unchanged at normal urinary pH. When the urinary pH is basic, amphetamine is in its free base form, so less is excreted. When urine pH is abnormal, the urinary recovery of amphetamine may range from a low of 1% to a high of 75%, depending mostly upon whether urine is too basic or acidic, respectively. Following oral administration, amphetamine appears in urine within 3 hours. Roughly 90% of ingested amphetamine is eliminated 3 days after the last oral dose.
CYP2D6, dopamine β-hydroxylase (DBH), flavin-containing monooxygenase 3 (FMO3), butyrate-CoA ligase (XM-ligase), and glycine N-acyltransferase (GLYAT) are the enzymes known to metabolize amphetamine or its metabolites in humans. Amphetamine has a variety of excreted metabolic products, including 4-hydroxyamphetamine, 4-hydroxynorephedrine, 4-hydroxyphenylacetone, benzoic acid, hippuric acid, norephedrine, and phenylacetone. Among these metabolites, the active sympathomimetics are 4-hydroxyamphetamine, 4-hydroxynorephedrine, and norephedrine. The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination. The known metabolic pathways, detectable metabolites, and metabolizing enzymes in humans include the following:

## History, society, and culture

Racemic amphetamine was first synthesized under the chemical name "phenylisopropylamine" in Berlin, 1887 by the Romanian chemist Lazăr Edeleanu. It was not widely marketed until 1932, when the pharmaceutical company Smith, Kline & French (now known as GlaxoSmithKline) introduced it in the form of the Benzedrine inhaler for use as a bronchodilator. Notably, the amphetamine contained in the Benzedrine inhaler was the liquid free-base, not a chloride or sulfate salt.
Three years later, in 1935, the medical community became aware of the stimulant properties of amphetamine, specifically the dextroamphetamine isomer, and in 1937 Smith, Kline, and French introduced tablets under the brand name Dexedrine. In the United States, Dexedrine was approved to treat narcolepsy and attention deficit hyperactivity disorder (ADHD). In Canada indications once included epilepsy and parkinsonism. Dextroamphetamine was marketed in various other forms in the following decades, primarily by Smith, Kline, and French, such as several combination medications including a mixture of dextroamphetamine and amobarbital (a barbiturate) sold under the brand name Dexamyl and, in the 1950s, an extended release capsule (the "Spansule"). Preparations containing dextroamphetamine were also used in World War II as a treatment against fatigue.
It quickly became apparent that dextroamphetamine and other amphetamines had a high potential for misuse, although they were not heavily controlled until 1970, when the Comprehensive Drug Abuse Prevention and Control Act was passed by the United States Congress. Dextroamphetamine, along with other sympathomimetics, was eventually classified as Schedule II, the most restrictive category possible for a drug with a government-sanctioned, recognized medical use. Internationally, it has been available under the names AmfeDyn (Italy), Curban (US), Obetrol (Switzerland), Simpamina (Italy), Dexedrine/GSK (US & Canada), Dexedrine/UCB (United Kingdom), Dextropa (Portugal), and Stild (Spain). It became popular on the mod scene in England in the early 1960s, and carried through to the Northern Soul scene in the north of England to the end of the 1970s.
In October 2010, GlaxoSmithKline sold the rights for Dexedrine Spansule to Amedra Pharmaceuticals (a subsidiary of CorePharma).
The U.S. Air Force uses dextroamphetamine as one of its "go pills", given to pilots on long missions to help them remain focused and alert. Conversely, "no-go pills" are used after the mission is completed, to combat the effects of the mission and "go-pills". The Tarnak Farm incident was linked by media reports to the use of this drug on long term fatigued pilots. The military did not accept this explanation, citing the lack of similar incidents. Newer stimulant medications or awakeness promoting agents with different side effect profiles, such as modafinil, are being investigated and sometimes issued for this reason.

### Formulations

#### Transdermal dextroamphetamine patches

Dextroamphetamine is available as a transdermal patch containing dextroamphetamine base under the brand name Xelstrym.

#### Dextroamphetamine sulfate

In the United States, immediate release (IR) formulations of dextroamphetamine sulfate are available generically as 5 mg and 10 mg tablets, marketed by Barr (Teva Pharmaceutical Industries), Mallinckrodt Pharmaceuticals, Wilshire Pharmaceuticals, Aurobindo Pharmaceutical USA and CorePharma. Previous IR tablets sold under the brand names Dexedrine and Dextrostat have been discontinued but in 2015, IR tablets became available by the brand name Zenzedi, offered as 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 30 mg tablets. Dextroamphetamine sulfate is also available as a controlled-release (CR) capsule preparation in strengths of 5 mg, 10 mg, and 15 mg under the brand name Dexedrine Spansule, with generic versions marketed by Barr and Mallinckrodt. A bubblegum flavored oral solution is available under the brand name ProCentra, manufactured by FSC Pediatrics, which is designed to be an easier method of administration in children who have difficulty swallowing tablets, each 5 mL contains 5 mg dextroamphetamine. The conversion rate between dextroamphetamine sulfate to amphetamine free base is .728.
In Australia, dexamfetamine is available in bottles of 100 instant release 5 mg tablets as a generic drug or slow release dextroamphetamine preparations may be compounded by individual chemists. In the United Kingdom, it is available in 5 mg instant release sulfate tablets under the generic name dexamfetamine sulfate as well as 10 mg and 20 mg strength tablets under the brand name Amfexa. It is also available in generic dexamfetamine sulfate 5 mg/ml oral sugar-free syrup. The brand name Dexedrine was available in the United Kingdom prior to UCB Pharma disinvesting  the product to another pharmaceutical company (Auden Mckenzie).

#### Lisdexamfetamine

Dextroamphetamine is the active metabolite of the prodrug lisdexamfetamine (L-lysine-dextroamphetamine), available by the brand name Vyvanse (Elvanse in the European market) (Venvanse in the Brazil market) (lisdexamfetamine dimesylate). Dextroamphetamine is liberated from lisdexamfetamine enzymatically following contact with red blood cells. The conversion is rate-limited by the enzyme, which prevents high blood concentrations of dextroamphetamine and reduces lisdexamfetamine's drug liking and abuse potential at clinical doses. Vyvanse is marketed as once-a-day dosing as it provides a slow release of dextroamphetamine into the body. Vyvanse is available as capsules, and chewable tablets, and in seven strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The conversion rate between lisdexamfetamine dimesylate (Vyvanse) to dextroamphetamine base is 29.5%.

#### Adderall

Another pharmaceutical that contains dextroamphetamine is commonly known by the brand name Adderall. It is available as immediate release (IR) tablets and extended release (XR) capsules. Adderall contains equal amounts of four amphetamine salts:

One-quarter racemic (d,l-)amphetamine aspartate monohydrate
One-quarter dextroamphetamine saccharate
One-quarter dextroamphetamine sulfate
One-quarter racemic (d,l-)amphetamine sulfate
Adderall has a total amphetamine base equivalence of 63%. While the enantiomer ratio by dextroamphetamine salts to levoamphetamine salts is 3:1, the amphetamine base content is 75.9% dextroamphetamine, 24.1% levoamphetamine.

## Research

### Schizophrenia

Dextroamphetamine reduces the negative symptoms of schizophrenia, and has been shown to enhance the effects of auditory discrimination training in schizophrenic patients.

## Reference notes
`,
};
